Physician profile
Dennis Carter
NPI 1831287630
$10,040.50
in general payments reported to CMS, 2019-2025
54 companies · $2,369 in 2025
The $2,369 reported for 2025 was more than what 97% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,210 · 2020: $1,124 · 2021: $1,220 · 2022: $1,643 · 2023: $1,137 · 2024: $1,338 · 2025: $2,369.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,784 · Education: $60.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,783.78 |
| Education | $60.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $1,195.52 | 2019-2025 | Breztri, Farxiga, Airsupra |
| Novo Nordisk INC | $931.06 | 2019-2025 | Ozempic, Rybelsus, Saxenda |
| Lilly USA, LLC | $750.95 | 2019-2025 | Jardiance, Mounjaro, Zepbound |
| Abbvie INC. | $651.40 | 2021-2025 | Vraylar, Ubrelvy |
| Astellas Pharma US INC | $559.92 | 2019-2025 | Veozah |
| Pfizer INC. | $530.97 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $449.73 | 2019-2024 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $393.81 | 2022-2025 | Caplyta |
| Boehringer Ingelheim Pharmaceuticals, INC. | $386.68 | 2019-2025 | Jardiance, Synjardy |
| Merck Sharp & Dohme LLC | $344.99 | 2019-2025 | Verquvo, Belsomra, Lagevrio |
| Bayer Healthcare Pharmaceuticals INC. | $326.83 | 2023-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $311.45 | 2019-2025 | Xifaxan, Trulance |
| Janssen Pharmaceuticals, INC | $291.59 | 2019-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $248.49 | 2019-2024 | Trintellix |
| Sumitomo Pharma America, INC. | $244.98 | 2023-2025 | Gemtesa |
Show all 54 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Dennis Carter listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.